Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:1.10.3.2 (
laccase
)
4,656
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In this study, cage-like mesoporous silica was used as the carrier to immobilize
laccase
by a physical approach, followed by encapsulating with chitosan/alginate microcapsule membranes to form microcapsules of immobilized
laccase
based on layer-by-layer technology. The relationship between
laccase
activity recovery/leakage rate and the coating thickness was simultaneously investigated. Because the microcapsule layers have a substantial network of pores, they act as semipermeable membranes, while the
laccase
immobilized inside the microcapsules acts as a processing plant for degradation of 2,4-dichlorophenol. The microcapsules of immobilized
laccase
were able to degrade 2,4-dichlorophenol within a wide range of 2,4-dichlorophenol concentration, temperature and pH, with mean degradation rate around 62%. Under the optimal conditions, the thermal stability and reusability of immobilized
laccase
were shown to be improved significantly, as the removal rate and degradation rate remained over 40.2% and 33.8% respectively after 6cycles of operation. Using mass spectrometry (MS) and nuclear magnetic resonance (NMR),
diisobutyl phthalate
and dibutyl phthalate were identified as the products of 2,4-dichlorophenol degradation by the microcapsules of immobilized
laccase
and
laccase
immobilized by a physical approach, respectively, further demonstrating the degradation mechanism of 2,4-dichlorophenol by microcapsule-immobilized
laccase
.
...
PMID:Cagelike mesoporous silica encapsulated with microcapsules for immobilized laccase and 2, 4-DCP degradation. 2670 68